IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease trial in region

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease trial in region
DUBAI, 11th July, 2024 (WAM) – IROS, an Abu Dhabi-based contract research organisation (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial for Huntingto...